Results 191 to 200 of about 2,867,772 (256)

Prevalence of pregnancy and birth outcomes following biologic exposure in immune‐mediated inflammatory diseases: A population‐based study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Almost 5% of pregnancies are affected by immune‐mediated inflammatory diseases (IMIDs). As treatments become available, understanding their use during pregnancy is important. We aimed to describe maternal, pregnancy and infant outcomes among IMID pregnancies exposed to biologic therapies. Methods Using the Merative™ MarketScan® Commercial Database,
Leah K. Flatman   +3 more
wiley   +1 more source

Safety and pharmacokinetics of inhaled aloxistatin: A first‐in‐human phase 1 dose escalation trial

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Aloxistatin (E64d) is a membrane‐permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first‐in‐human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers.
Sebastian Fähndrich   +24 more
wiley   +1 more source

The Impact of Aging on the Anatomical Course of the Azygos Vein: A Retrospective, Computed Tomography Study

open access: yesClinical Anatomy, EarlyView.
ABSTRACT The azygos vein (AV) is typically described as ascending vertically to the right of the vertebral column before arching anteriorly to drain into the superior vena cava. However, a small number of studies suggest that it is found leftward in older adults.
Lauren R. Hector   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy